MiniMed Group (NASDAQ:MMED) Now Covered by Barclays

Barclays initiated coverage on shares of MiniMed Group (NASDAQ:MMED) in a report released on Wednesday morning,Benzinga reports. The firm issued an overweight rating and a $26.00 target price on the stock.

Other equities research analysts also recently issued research reports about the company. BTIG Research initiated coverage on MiniMed Group in a research report on Tuesday. They set a “buy” rating and a $25.00 price target on the stock. Wells Fargo & Company started coverage on MiniMed Group in a research report on Tuesday. They set an “overweight” rating and a $26.00 price objective on the stock. Bank of America began coverage on MiniMed Group in a report on Tuesday. They set a “buy” rating and a $27.00 price objective on the stock. Evercore initiated coverage on MiniMed Group in a research report on Tuesday. They issued an “outperform” rating and a $20.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of MiniMed Group in a research report on Tuesday. They set a “buy” rating and a $20.00 price target on the stock. Eleven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, MiniMed Group has a consensus rating of “Moderate Buy” and a consensus price target of $22.45.

MiniMed Group Price Performance

NASDAQ MMED opened at $14.48 on Wednesday. MiniMed Group has a 52-week low of $14.10 and a 52-week high of $20.48.

MiniMed Group News Roundup

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Bank of America initiated coverage with a Buy rating and a $27 price target, highlighting pipeline-driven growth after the Medtronic separation. Article Title
• Positive Sentiment: Barclays started covering MMED with an Overweight rating and a $26 target, signaling strong upside expectations. Article Title
• Positive Sentiment: Wells Fargo initiated coverage with an Overweight rating and a $26 price target, aligning with other firms on material upside potential. Article Title
• Positive Sentiment: Goldman Sachs initiated a Buy rating with a $24 target, another high-profile bank backing the story. Article Title
• Positive Sentiment: BTIG, Citigroup and Mizuho all opened coverage with Buy/Outperform calls and targets in the low-to-mid $20s, adding to the consensus of meaningful upside from current levels. Article Title
• Positive Sentiment: Evercore, Deutsche Bank and Morgan Stanley also initiated coverage with Outperform/Buy or Overweight views and targets between $19–$21, broadening institutional coverage. Article Title
• Neutral Sentiment: Piper Sandler set a Neutral/16 price target and, separately noted by TipRanks, issued a Hold—this is a more cautious view relative to the slate of Buy calls. Article Title
• Negative Sentiment: Despite the bullish analyst initiation wave, the stock is trading down today — suggesting short-term selling, profit-taking, or market-wide weakness is offsetting the new coverage (no single negative company-specific event reported).

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.